Shares of Antares Pharma Inc (NASDAQ:ATRS) have been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $4.83.
A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $4.50 price objective on shares of Antares Pharma in a research note on Monday, May 6th. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research report on Thursday.
Shares of Antares Pharma stock traded down $0.09 during trading hours on Monday, reaching $2.96. The company’s stock had a trading volume of 18,515 shares, compared to its average volume of 952,002. Antares Pharma has a one year low of $2.53 and a one year high of $3.96. The stock has a market cap of $495.99 million, a P/E ratio of -74.00 and a beta of 0.95. The business has a fifty day simple moving average of $3.16. The company has a quick ratio of 1.90, a current ratio of 2.28 and a debt-to-equity ratio of 0.50.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Antares Pharma had a negative net margin of 7.91% and a negative return on equity of 17.94%. The firm had revenue of $23.29 million for the quarter, compared to analyst estimates of $17.46 million. As a group, equities analysts forecast that Antares Pharma will post -0.1 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the business. Corrado Advisors LLC bought a new stake in Antares Pharma in the second quarter worth about $26,000. Alpine Woods Capital Investors LLC purchased a new position in shares of Antares Pharma in the first quarter worth about $30,000. Aperio Group LLC purchased a new position in shares of Antares Pharma in the second quarter worth about $47,000. Enterprise Bank & Trust Co purchased a new position in shares of Antares Pharma in the first quarter worth about $45,000. Finally, Searle & CO. purchased a new position in shares of Antares Pharma in the first quarter worth about $61,000. 43.05% of the stock is currently owned by institutional investors and hedge funds.
About Antares Pharma
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Featured Story: Call Option
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.